Moleculin Biotech Stock Today
| MBRX Stock | USD 1.04 0.05 4.59% |
PerformanceInsignificant
| Odds Of DistressLow
|
Moleculin Biotech is trading at 1.04 as of the 20th of March 2025; that is 4.59 percent decrease since the beginning of the trading day. The stock's open price was 1.09. Moleculin Biotech has less than a 15 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of June 2016 | Category Healthcare | Classification Health Care |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. The company has 12.01 M outstanding shares of which 2.2 M shares are now shorted by private and institutional investors with about 0.08 trading days to cover. More on Moleculin Biotech
Moving together with Moleculin Stock
Moving against Moleculin Stock
Moleculin Stock Highlights
| Chairman, CoFounder | Walter Klemp | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMoleculin Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moleculin Biotech's financial leverage. It provides some insight into what part of Moleculin Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Moleculin Biotech (MBRX) is traded on NASDAQ Exchange in USA. It is located in 5300 Memorial Drive, Houston, TX, United States, 77007 and employs 18 people. Moleculin Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.09 M. Moleculin Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.01 M outstanding shares of which 2.2 M shares are now shorted by private and institutional investors with about 0.08 trading days to cover.
Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Moleculin Biotech Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Moleculin Biotech is $13.09 Million. Roughly 95.76 % of Moleculin Biotech outstanding shares are held by general public with 0.75 pct. owned by insiders and only 3.49 % by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Moleculin Ownership Details
Moleculin Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 426 | |
| Sbi Securities Co Ltd | 2024-12-31 | 405 | |
| Bogart Wealth, Llc | 2024-12-31 | 300 | |
| Bank Of America Corp | 2024-12-31 | 104 | |
| Sandy Spring Bank | 2024-12-31 | 89.0 | |
| Cva Family Office, Llc | 2024-12-31 | 34.0 | |
| Kestra Investment Management, Llc | 2024-12-31 | 25.0 | |
| North Star Investment Management Corp | 2024-12-31 | 17.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Armistice Capital, Llc | 2024-12-31 | 317.6 K | |
| Lpl Financial Corp | 2024-12-31 | 41.2 K |
Moleculin Biotech Historical Income Statement
Moleculin Stock Against Markets
Moleculin Biotech Corporate Management
| Louis Ploth | Independent Advisor | Profile | |
| ScD MD | Senior Officer | Profile | |
| Jacqueline Northcut | Consultant | Profile | |
| Donald Picker | Chief Officer | Profile | |
| Waldemar Priebe | Founding CoFounder | Profile |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.